Anpac Bio Surpasses 50,000 Situation Study Milestone ‘Liquid Biopsy Pioneer’ Serving Individual, Medical, Insurance & Corporate Customers

SACRAMENTO, Calif., March. 17, 2017 /PRNewswire/ — Dr. Chris Yu, Ceo of worldwide existence sciences corporation Anpac Bio-Medical Science Company, announced now the organization set a brand new, worldwide record, processing and reporting 50 plus,000 cases worldwide from the company’s proprietary, “Cancer Differentiation Analysis” (CDA) liquid biopsy tests.

Referred to as “game altering”, and finding the, “Breakthrough Innovation Award”, at World Nobel Prize Laureate Summit and named, “Most Promising Cancer Screening Company”, in the 2017 Global Precision Medicine Industry Awards, Anpac Bio’s CDA technology effectively reinvents early cancer screening and recognition.

By analyzing simple, standard, bloodstream tests, and applying Anpac Bio’s proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio’s CDA technology identifies cancer with measurably-greater precision than most up to date, conventional screening methods. Also it achieves this with no dangerous negative effects in patients generating far less “false positives” at a price substantially less than traditional testing and generating results in a few minutes of sample submission.

Comprehensive research validity data in the 50,000+ cases processed up to now demonstrate CDA diagnostics consistently identify over 26+ cancers — having a sensitivity and specificity rate selection of 75%-90% — usually identifying the condition at its earliest stages.

The organization has filed over 200 CDA-related patent applications worldwide – 65+ issued presently and maintains operations in six sites, employing over 100 people globally.

“Since our organization launched in 2008, Anpac Bio has pioneered the ‘liquid biopsy’ space,” states Dr. Yu. “Our CDA technologies have been extensively tested, verified, and used daily by a large number of Asia’s best-respected and famous medical institutions. We’re also generating equally accurate and good results in the U . s . States. So that as these studies continues to be printed and presented before respected scientific organizations, like the American Society of Clinical Oncology (ASCO) and also the World Nobel Prize Laureate Summit, our CDA exams are in great demand. We are now processing CDA tests for people, health systems, insurance providers, educational facilities, and corporations. We are very proud our CDA devices have advanced past the laboratory, and therefore are processing real tests legitimate people – saving lives every single day. Only at that rate, we project to double our CDA cases worldwide and save a lot more resides in 2018!”

To learn more about Anpac Bio book: world wide

View original quite happy with multimedia:http://world wide–corporate-customers-300538549.html

SOURCE Anpac Bio-Medical Science Company

Related Links

http://world wide

LEO Science & Tech Hub, Elektrofi to succeed formulation technology for dermatological drug delivery

Printed 12 October 2017

LEO Science & Tech Hub, an R&D unit of LEO Pharma, has signed a cooperation agreement with Cambridge-based biotechnology company Elektrofi to understand more about advanced formulation technology for dermatological drug delivery.

“We are excited to announce this collaboration with Elektrofi to understand more about its innovative Elektroject™ process technology to improve our options in subcutaneous delivery of antibodies,” stated Michael Sierra, Ph.D., VP of LEO Science & Tech Hub.

“Developing therapeutic solutions that aren’t only effective and safe but additionally convenient for patients with skin illnesses is crucial to improving patient experience and outcomes, that is a goal the Hub strives to attain.Inches

Elektrofi leverages a singular therapeutic microparticle suspension system (Elektroject™) to engineer high-concentration, low-viscosity antibody formulations. Even though many antibody formulations become virtually unusable at high concentrations because of high viscosity, Elektroject™ suspensions lead to antibody concentrations which are greater than 15x the typically administered concentration without exceeding viscosity limits.

This permits medical professionals to subcutaneously administer high doses of antibody-based therapies inside a relatively small volume within a few moments.

“We are thinking about creating a paradigm transfer of drug delivery to dramatically enhance the lives of patients,” stated Jason Norris, Co-Founding father of Elektrofi.

“LEO Science & Tech Hub is really a leader in speeding up precision medicine in skin care, and we’re happy to enter this collaboration that will combine Elektrofi’s operate in transforming drug delivery using the Hub’s knowledge of skin care.”

The LEO Science & Tech Hub is acknowledged for its collaborative approach of seeking cutting-edge technology for dermatological applications.

Inside the newbie of their launch, The Hub has effectively created multiple collaborations to understand more about non-invasive biomarker technologies, drug delivery technology, and advanced imaging technology with leading research institutes and biotechnology companies, such as the Karp Lab, Novopyxis, and also the Wellman Center for Photomedicine at Massachusetts General Hospital.

Source: Company Pr Release

Synaptive Medical unveils next-gen surgical robotics

Printed 10 October 2017

Synaptive Medical features Modus V, that is a second-generation and-powered digital microscope having a surgical automatic arm comes from Canadarm technology utilized on the Worldwide Space Station.

Made with feedback from Synaptive’s clinical partners, Modus V may be the new cornerstone of their integrated BrightMatter platform.

Modus V sets the brand new standard for robot-aided neurosurgery most abundant in effective optics in the marketplace that provide unparalleled views of patient anatomy and could allow surgeons to do less invasive procedures with increased precision.

For patients, less invasive procedures can lead to faster recovery occasions, reduced complications and, in some instances, may render an inoperable diagnosis operable.

For surgeons, Modus V’s advanced instrument tracking with auto-focus, coupled with a very flexible arm, also enables for elevated surgical efficiency through hands-free control, better ergonomics during procedures and greater versatility within the operating room.

These innovations feed developments in precision medicine by making more chance to capture, evaluate and draw trends from patient data and make better decision-making tools for physicians, researchers and hospital managers.

“This product release marks a significant milestone within our evolution like a company,” states Peter Wehrly, Synaptive’s Chief executive officer. “Modus V is an essential part in our overall BrightMatter surgical solution.

“Conceptualized for that digital era like a fully integrated group of devices, our solution collects and delivers data—be it imaging, tractography or any other patient information—when where it’s most required to drive surgical making decisions. It’s a part of our ongoing dedication to give surgeons probably the most advanced tools that to deal with their sufferers.Inches

Modus V belongs to the BrightMatter product suite, which transforms surgical planning, patient data collection and intraoperative vision from disjointed analog techniques to a completely integrated platform with navigation, automatic automation, digital microscopy and knowledge analytics.

Because the successor to BrightMatter Drive, Synaptive’s first generation automatic digital microscope, Modus V’s improved design was produced to satisfy the complex requirements of cutting-edge surgery, including:

Probably the most effective optics platform available on the market fully integrated using the automatic arm, supplying superior visualization of anatomy and permitting better making decisions if this matters most

Enhanced hands-free tracking of surgical instruments with auto-focus and programmable motions gives surgeons additional control without disrupting workflow

Elevated arm versatility covers a bigger amount of space, permitting handier positioning round the patient and ergonomic alignments of optics for that surgeon

Smaller sized unit footprint enables for greater maneuverability within the OR and enables faster deployment

“Collaboration is hardwired into Synaptive’s culture. Modus V’s enhancements are grounded within the collaboration and extensive feedback from neurosurgeons within our customer community on Modus V prototypes and BrightMatter Drive,” states Cameron Piron, Synaptive’s president and chief strategy officer.

Source: Company Pr Release

New wellness study shows precisely how sticky wearables could be, even among seniors


Quantifying the potency of wearables to improve activity inside the framework of the payer or employer wellness program continues to be the origin in excess of a couple of studies. Can financial incentives from all of these groups also steer participants towards the preferred outcome? Will participants be sufficiently engaged to make use of these wearables more than a lengthy time period? What are the characteristics of the long run users?

El born area is a subject of great interest for Dr. Mitesh Patel, a helper professor of drugs and Healthcare Management at College of Pennsylvania Perelman Med school and also the Wharton School in addition to director of Penn Medicine’s Nudge Unit.

However the curiosity about increasing the sustained utilization of wearables goes past employer programs, based on the Annals of Internal Medicine study. Additionally, it pertains to data collection for precision medicine initiatives to higher target interventions.

With what Patel stated may be the largest study available to judge the stickiness of wearables inside a step counting program, 4.4 million Humana wellness program people were asked to participate. Of individuals, 55,000 really downloaded the appropriate application for that study, that was printed in Annals of Internal Medicine.

Researchers examined data for any two-year period from 2014-2015 and tracked when participants first activated their activity tracker, how often the unit was utilized within the first six several weeks following activation, average daily step counts and sociodemographic characteristics, based on a news release from Penn.

Inside a phone interview Patel stated he was struck that although .2 percent used the devices in year one, that rose to at least one.2 percent in year two. In six several weeks, 80 % of those who began while using device remained as utilizing it.

Possibly unsurprisingly, a lot of the individuals who required an energetic role within the study were rather youthful coupled with greater-incomes than individuals who didn’t make use of the devices. What struck Patel was that although only .1 % of individuals over the age of 65 activated a tool, 90 % of those participants remained as with them six several weeks later. There might be less wearables users who’re seniors however they stay with them, which reflects the study’s findings.

“We discovered that though use increased with time, it truly varied based on individual characteristics like age and earnings,” Patel stated in news reports release. “We also discovered that once someone began utilizing an activity tracker, sustained use at six several weeks was high at 80 %.Inches

Although 60 wearables might be utilized in this program, FitBit trackers dominated and taken into account 76 percent from the trackers utilized by participants. Its nearest was Apple’s devices at 9 %, the discharge noted.

Fitbit announced a study of their own on guidelines for employer wellness programs. It’s also profiled users by their “fitness personas” — the kinds of activities that have a tendency to resonate together according to how old they are and the way to best engage them within an employer wellness setting.

Amy McDonough, Senior V . P ., Strategy and processes, Fitbit Health Solutions responded by email to questions regarding how employer wellness programs might be better made to improve participation across an assorted group of ages and preferences. She could not agree that age had an effect on level of fitness.

“Fitness level doesn’t always correlate as we grow older therefore it may be preferable to define your workforce based on fitness personas instead of generations. This angle will help you interact with employees according to their physical fitness goals, it doesn’t matter what age they’re. It is also useful to consider intrinsic and extrinsic motivations, playing towards the different personas with incentives.”

Photo: fandijki, Getty Images

Phosphorus Launches Diagnostic Ophthalmology and Drug Response Genetic Tests

NEW You are able to, Sept. 13, 2017 /PRNewswire/ — Phosphorus, a computational genomics company, announced today adding two advanced genetic tests to the catalogue: An ophthalmologic test for inherited conditions connected with vision loss and blindness, along with a pharmacogenomic test to look at the effectiveness of numerous drugs for particular patients, based on their genes. The most typical retinal disorder around the ophthalmologic test, retinitis pigmentosa, claims an incidence rate of one in three.5 1000 individuals (Haim, 2002)1, along with other conditions tested exhibiting high incidence rates too. Similarly, genetics also take into account 20-95% of variability as a result of individual drugs (Kalow et al, 1998)2, with 10-20% of adverse drug reactions potentially associated with genetics (Ingelman-Sundberg, 2004)3.

Phosphorus’ new tests range from the very indepth panels of genes in line with the latest advances in research. They’ll be unveiled in the National Society of Genetic Counselors (NSGC) Annual Conference in Columbus, Ohio now.

“For inherited retinal disorders, dna testing may be used to prevent vision loss and blindness,” described Oscar Puig, Chief Scientific Officer at Phosphorus. “Furthermore, our new genetic tests for drug response will equip patients with information about how to higher optimize their medication.”

Phosphorus’ expert-curated panels, effective data analytics, and rigorous variant interpretations happen to be developed and designed to guarantee the most accurate recent results for patients. The exams are operated by next-generation sequencing technology, including comprehensive recognition of copy number variants. The straightforward testing workflow is made to ease the procedure for physicians and supply an inexpensive choice for patients as well as their family people.

“Using the launch in our ophthalmologic and pharmacogenomic tests, we’re expanding our portfolio of diagnostic products, including comprehensive tests in cardiology, oncology, and reproductive health. By pairing these studies with Phosphorus’ Elements software, we provide the very first finish-to-finish solution enabling laboratories and medical facilities to construct and expand their precision medicine abilities,” stated Alexander Bisignano, co-founder and Chief executive officer of Phosphorus.

The recently launched ophthalmology genetic test includes the next conditions:

  • Retinal Disorders: 146 genes. Includes genes connected with achromatopsia, Bardet-Biedl syndrome, cone-fishing rod dystrophy, Usher syndrome, hereditary stationary night blindness, Leber hereditary amaurosis, retinitis pigmentosa, and macular dystrophy.
  • Cataracts: 38 genes. Hereditary cataracts are the most typical reason for treatable childhood blindness, with 25-33% of cases being hereditary4.
  • Glaucoma: 18 genes. Early-onset glaucoma can result from hereditary conditions.
  • Corneal Dystrophy: 8 genes. About one in 1,000 people includes a corneal dystrophy that can result in vision loss after lasek5.

The recently launched drug response genetic test covers probably the most generally prescription drugs across a sizable mix portion of therapeutic areas, including cardiology, psychiatry, oncology, discomfort management, neurology, immunology, gastroenterology, respiratory system, infectious disease, yet others.

Find out more about Phosphorus tests in the National Society of Genetic Counselors Annual Conference in Columbus, Ohio at booth #350. See the company’s research poster presentation, “Obvious Indication for Cardiogenetics Testing Not Good GC Referral Options. How Can Genetic Counselors Think a Cardiologist Should Proceed?,” on Wednesday, September 13, 2017 from 5:15 PM to six:30 PM (poster A-10). See the company’s other research poster presentation, “CDC Tier 1 Genomic Applications: Awareness Among GCs and Potential Effect on GC Practices,” on Friday, September 15, 2017 from 1:15 to two:30 PM (poster C-9). Both presentations is going to be delivered within the exhibit hall.

About Phosphorus

Phosphorus is really a computational genomics company using the vision to produce a world where every healthcare decision is enhanced with genomics. Headquartered in New You are able to City, Phosphorus offers clinical genetic tests in a variety of clinical areas from the CLIA-certified laboratory. The organization also develops effective software that allows labs all over the world to provide probably the most advanced genetic tests. Phosphorus’ active development and research program comes with an initial concentrate on decoding the genetic reasons for infertility and inherited coronary disease. Having a group of experts in computational biology and information technology, Phosphorus is creating a data network that can help providers, researchers and patients all over the world better understand and harness the strength of a persons genome. To learn more visit: world wide and @phosphorus.

1Haim M. Epidemiology of retinitis pigmentosa in Denmark. Acta Ophthalmol Scand Suppl. 2002(233):1-34.
2Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can replacement for twin studies in drug research. Pharmacogenetics. 19988(4):283–289.
3Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and it is applications in drug therapy: yesteryear, present and future. Trends Pharmacol Sci. 200425(4):193-200.
4Yi J. et al. (2011). Int J Ophthalmol, 4(4), 422-32.
5Lee J. et al. (2010). Ophthalmic Epidemiology, 17(3), 160-165.

View original quite happy with multimedia:http://world wide

SOURCE Phosphorus

Related Links

Three methods to enhancing medical trial recruitment

Considering that numerous studies represent the greatest discomfort point for drug development in the painstakingly slow recruitment process and the necessity to discover the most appropriate candidates, it’s interesting to determine how information mill dealing with the task in their own individual unique way. Now, three different companies made news now regarding the way they were attempting to enhance the recruitment experience for patients as well as for pharma companies.

The team at Facebook, a social networking that has formerly hinted in a variety of ways in which it thinking about being more involved with healthcare, located a breakfast for drug marketers to describe a brand new medical trial strategy thiis week. It spoken about how exactly drug companies may use its vast network to recognize and discover medical trial candidates and remain around the right side from the law, based on a CNBC article.

Organizations like the Michael J Fox Foundation have had the ability to cut costs making recruitment more effective by advertising for numerous studies online. This past year MJFF found they could save a boatload on the price of ads in contrast to traditional advertising strategies and also the organization could boost recruitment substantially.

Now, Antidote Technologies elevated $11 million inside a Series A round because of its medical trial matching business brought by Merck Global Health Innovation Fund with participation from existing investors Smedvig Capital and Octopus Ventures.

Antidote includes a medical trial search tool in excess of 180 patient communities and health portals within the U.S. and United kingdom. Users complete a questionnaire to allow them to find out the best numerous studies nearby. A few of the company’s medical trial tools are highlighted on its website. For instance, an “Antidote Bridge” gives procedure descriptions, the number of overnight stays, placebo use, and financial compensation details to patients for every trial. Antidote API helps you to screen patients for many numerous studies at the same time. The fundraise can help the company harness data from EHRs because of its trial matching platform towards precision medicine.

The clinical trial matching service contends that 80 % of numerous studies have to shut lower prematurely simply because they don’t recruit enough participants. The concept is to really make it simpler for patients to locate relevant trials, in addition to nurses and doctors. Still, physicians and nurses stated they often times decline to touch on patients to numerous studies due to the lack of ability to gain access to information or inadequate details are available about numerous studies, based on a January report from Tufts Center for study regarding Drug Development.

VitalTrax now launched Wing, an item made to simplify the job to find trials having a user friendly interface. Users can look for trials by hitting fundamental criteria for example gender, location, and condition, but they may also choose the status from the study, the kind of trial, and also the phase from the medical trial. Design and also the choices are less confusing than, say, searching of numerous

Photo: elenabs, Getty Images

To raise diagnostics, the unloved stepchild of precision medicine, educate, educate and educate

educate, teach, learn

Precision prescription medication is built on the concept that medicine will find better solutions for individual patients. Oncology may be the go-to example. An EGFR (epidermal growth factor receptor) inhibitor could be a winning therapy, provided the individual has mutant EGFR proteins driving their cancer. This is where diagnostics are available in.

This is where diagnostics are available in.

But to date, diagnostics happen to be a difficult sell. While they’re essential to fulfill precision medicine’s promise, nobody desires to purchase them. Diagnostics might be precision medicine’s unloved stepchildren and it is incumbent that healthcare stakeholders understand their value.

“If you appear at magazine cover after magazine cover…every time they discuss personalized medicine what’s around the cover? A medication,Inches stated Mara Aspinall, president and Chief executive officer at Health Catalysts towards the audience in the lately-concluded Precision Medicine Leaders Summit. “Somehow, there’s no acknowledgment of the significance of diagnostics.”

Throughout a panel discussing methods to move diagnostics to the forefront of precision medicine, Aspinall noted that in the past diagnostics have helped advance groundbreaking therapies. Broad microbial testing added value to antibiotics. Disease portrayal improved chemotherapy’s effectiveness against bloodstream cancers. Viral load measurements enhanced antiviral cocktails for AIDS patients.

As the relationship between drugs and diagnostics may appear self-apparent, the 2 disciplines don’t always collaborate.

“Pharma doesn’t understand diagnostics diagnostics (companies) don’t understand co-growth and development of drugs,” stated Tricia Carrigan, global mind of translational assay technology for Bayer. “Every pharma is attempting compare unique car features in personalized medicine. Regrettably, its not all disease has obvious biomarker signatures. We all do need the strength of the city and also the AI and also the deep understanding how to harmonize the information therefore we have better signatures.”

Another significant problem is financial support. Because payers don’t always value their goods, diagnostic companies could be uncertain investments.

“Investors are scared [of] purchasing these companies,” stated Don Hardison, president and Chief executive officer at Biotheranostics. “If you may well ask them why they’re not investing, it more often than not returns for you to get compensated. If the reply is that you’re getting compensated $ 10, could it be even worth doing?”

Early collaboration may help diagnostics companies overcome this barrier. It’s vital that you gauge the marketplace and drive development accordingly.

“It’s very hard to allow them to enter the marketplace using the current reimbursement,” stated Hannah Mamuszka, founder and Chief executive officer at Alva10. “Engaging payers earlier, along with the regulatory process, to determine what sort of value a specific test will obtain available on the market. That’s where one can alter the financial aspects and obtain the investors in your corner.Inches

Regrettably, payer outreach frequently uses the merchandise is developed, which might not be optimal.

“If you’re the payer, consider someone turning up at the door and saying: ‘Hi, pay me. Here’s something didn’t know you desired or you don’t want,” stated Mamuszka.

Mary Stevens, director of network contracts, compliance, audit and provider relations at Blue Mix Blue Shield of Minnesota – the payer around the panel – believes insurance providers have to be educated about diagnostics, but that’s only area of the picture. Physicians and patients should be onboard too. Patients frequently ask their doctors for particular medications they’ve seen on tv, but rarely recognize the significance of diagnostics.

“The people are educated on individuals things,” stated Stevens, “they aren’t educated on diagnostics and that has got to change.”

The panel frequently came back to education. Physicians, pharma companies, and payers don’t always begin to see the benefits. However, that does not mean they’re uninterested.

“You can’t value something should you not comprehend it,Inches stated Stevens. “There is definitely an appetite for true innovation…There needs to be an easy method to describe that something truly is totally new.Inches

While payers continue to be behind the bend, VCs appear to become swept up with regards to purchasing diagnostics companies.

Photo: A-Digit, Getty Images